Background
Foravirumab (CR4098), is currently under phase II clinical trial in the form of a cocktail with rafivirumab (CR57), a mAb derived from somatic cell hybridization targeting rabies virus glycoprotein antigenic site I.• Structure and function of respiratory syncytial virus surface glycoproteins., PMID:24362685• Full-length G glycoprotein directly extracted from rabies virus with detergent and then stabilized by amphipols in liquid and freeze-dried forms., PMID:34297405• Recombinant Soluble Henipavirus Glycoprotein Preparation., PMID:37610572• Ephedrae Herba and Cinnamomi Cortex interactions with G glycoprotein inhibit respiratory syncytial virus infectivity., PMID:35079103• VSV-G Viral Envelope Glycoprotein Prepared fromPichia pastorisEnhances Transfection of DNA into Animal Cells., PMID:28297751• Spatiotemporal transcriptomic mapping of regenerative inflammation in skeletal muscle reveals a dynamic multilayered tissue architecture., PMID:39190487• Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors., PMID:37199666• Evolutionary trends of respiratory syncytial viruses: Insights from large-scale surveillance and molecular dynamics of G glycoprotein., PMID:38784562• G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates., PMID:21693135• The use of monoclonal antibodies and lectins to identify changes in viral glycoproteins that are influenced by glycosylation: the case of human respiratory syncytial virus attachment (G) glycoprotein., PMID:17502674